Curriculum Vitae: Giulio Superti-Furga

Personal details:

Date of Birth:	17/05/1962
Place of Birth:	Milan, Italy
Nationality:	Italian
Spoken languages:	Italian, German, English, (French)
Acad. Degree:	PhD
Current Position:	Scientific Director and CEO of CeMM, Guest Professor of Molecular Pharmacology Med Univ Vienna
Address work:	CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences Lazarettgasse 14, AKH BT 25.3, 1090 Vienna, Austria Tel: + 43 1 40160 70001, Fax: + 43 1 40160 970000 e-mail: gsuperti@cemm.oeaw.ac.at,

Scientific Education and Career History:

1968 – 1981	German School of Milan
1981 – 1986	Diploma studies of Molecular Biology, University of Zurich (M.Busslinger, M.L. Birnstiel)
1987 – 1991	Ph.D. studies at University of Zurich, Genentech, Inc, and I.M.P. Vienna. Degree in Molecular Biology University of Zurich (M. Busslinger, M.L. Birnstiel)
1991 – 1993	Postdoctoral fellow European Molecular Biology Laboratory, Heidelberg (G. Draetta, S. Courtneidge)
1993 – 2004	Staff Scientist and Team Leader European Molecular Biology Laboratory
1997 – 2000	Adj. Professor of Molecular Biology at the University of Bologna
2000 – 2005	Founder and Scientific Director Cellzome AG and Inc., Heidelberg
2005 – present	Guest Professor of Molecular Pharmacology, Medical University of Vienna
2005 – present	Director CeMM

Other Functions	Chair, EMBL Alumni Association (1,800 members), Member of the Standing Technical Evaluation Committee of the Lombardy Region for Research Funds, Member of the Harvard Armenise Foundation Fellowship Committee (until 2012), Chair of the Committees awarding the FEBS Letters Young Group Leader Prize (until 2011) and of the John Kendrew Award of the EMBL Alumni Association, Member of the Ignaz L. Lieben Prize Committee and Jubiläumsfonds der Stadt Wien, member of non-partisan "Österreich 2025" Think-Tank (section "Innovationsland Österreich)
Scientific Advisory Board Member (selection)	IARC (International Agency for Cancer Research, Lyon, France), EAB Board Member Institute for Research in Biomedicine (IRB Barcelona), HSR San Raffaele (Milan), Cellzome Inc. (Heidelberg and Cambridge), Helmholtz Alliance on Systems Biology (Germany), Virtual Liver Network (largest Systems Biology in Europe, German Ministry), Austrian Association of Molecular Life Sciences and Biotechnology, SAB Expert Proteomics Panel Roche, Evaluation Board Chair VIB Ghent
Editorial work	Nature, Science, Cell, Molecular Cell, Cancer Cell, PNAS, EMBO Journal, PloS Biology, Plos Pathogen, Nature Chemical Biology, Nature Cell Biology, Nature Molecular and Structural Biology, Nature Biotechnology, Nature Methods, Molecular and Cellular Biology, Mol Biol of the Cell, Cell Growth and Differentiation, EMBO Molecular Medicine (Co-Editor), Oncogene, Genome Biology, Cancer Research, Leukemia *and many other*

Referee and Evaluator	EU (FPs, ERC LS2) DFG, BBSRC, MRC, CRUK, German/ Italian/ Austrian/ Slovenian Ministries of Science, Cariplo Foundation, DKFZ, Philip Morris, U. of Berkeley, U. of Pittsburgh, CNIO, IST-A, Med Uni Vienna, Childrens Cancer Res Inst Vienna, French Natl Cancer Inst, UMIT Univ for Life Sciences Tyrol, Biogen, Austrian Acad Sciences, Max Delbrück CMM Berlin, Qatar Biomedical Research Institute/Sidra Medical & Research Center *and many other*

Fellowships and Awards:

1991	EMBO and EU long-term fellowships
2004-2010	Faculty of 1000
2005	EMBO Member
2007	Corresponding Member of the Austrian Academy of Sciences
2008	Member of the German Academy of Sciences Leopoldina
2008	Dance your PhD Contest, *Science* Magazine, *winner professor category*
2009	Order of Merit of the Republic of Italy, Knight Officer
2009	Karl Landsteiner Prize by the Austrian Society of Allergology and Immunology
2009	Advanced Investigator Grant of the European Research Council
2010	Full Member of the Austrian Academy of Sciences
2010	Fellow of the European Academy of Cancer Sciences
2011	Science Prize of the City of Vienna
2011	Austrian of the Year, category researcher

Bibliography and Patents:

Publications:	122 in Pubmed, 191 publications, h-factor= 51 ISI web of Science [superti-furga g* OR supertifurga g* AND NOT power OR electric OR engineering]
Cited:	11,126 times (without self-citations),
Conf. organised	15
Invited Lectures:	> 200
Patents:	10

Research Interests:

(1) Proteome organization
(2) Molecular basis of innate immunity
(3) Molecular networks in leukemia
(4) Mechanism of action of drugs

Biosketch:

Giulio Superti-Furga is an Italian molecular and systems biologist. He performed his undergraduate and graduate studies in Molecular Biology at the University of Zurich, at Genentech Inc. in San Francisco and at the Research Institute of Molecular Pathology (IMP) in Vienna. He was a post-doctoral fellow at the European Molecular Biology Laboratory (EMBL) in Heidelberg and became Team Leader in 1995. From 1997 to 2000 he served as Guest Professor of Molecular Biology at the University of Bologna. In 2000, he co-founded the biotech company Cellzome Inc. and served as Scientific Director. Since 2005 he is Scientific Director of CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences and Visiting Professor of Molecular Pharmacology at the Medical University of Vienna. Amongst his most significant scientific achievements to date are the elucidation of basic regulatory mechanisms of tyrosine kinases in human cancers and the discovery of fundamental organization principles of the proteome of higher organisms, which is one of the most highly cited papers in the field. His current work focuses on protein complexes, molecular networks and drugs relevant for leukemia and host immune defense mechanisms against pathogens. He is an advocate for the adoption of systems biology approaches for medicine and aims to bridge basic research and the clinical world.

10 most important Publications:

1. Functional organization of a eukaryotic proteome: systematic analysis of multi-protein complexes in Saccharomyces cerevisiae. Gavin, A.C., Bosche M, Krause R, Grandi P, Marzioch M, Bauer A, Schultz J, Rick JM, Michon AM, Cruciat CM, Remor M, Hofert C, Schelder M, Brajenovic M, Ruffner H, Merino A, Klein K, Hudak M, Dickson D, Rudi T, Gnau V, Bauch A, Bastuck S, Huhse B, Leutwein C, Heurtier MA, Copley RR, Edelmann A, Querfurth E, Rybin V, Drewes G, Raida M, Bouwmeester T, Bork P, Seraphin B, Kuster B, Neubauer G, Superti-Furga G. ***Nature*** 2002 415, 141-147.
2. Autoinhibition of c-Abl. Pluk H, Dorey K, Superti-Furga, G. Cell 2002 108, 247-259.
3. A myristate/phosphotyrosine switch regulates c-Abl. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, Superti-Furga G. ***Cell*** 2003 112, 845-857.
4. A physical and functional map of the TNFα/NFκB signalling pathway. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari, G, Drewes G, Gavin AC, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, and Superti-Furga G. ***Nature Cell Biology*** 2004 6:97-105.
5. Proteome survey reveals modularity of the yeast cell machinery. Gavin AC, Aloy, P, Grandi P, Krause R, Boesche M, Marzioch M, Rau C, Jensen LJ, Bastuck S, Dümplefled B, Edelmann A, Heurtier MA, Hoffmann V, Hoefert C, Michon M, Schirle M, Remor M, Bauer A, Bouwmeester T, Casari G, Drewes, G, Neubauer G, Rick JM, Kuster B, Bork P, Russell RB, Superti-Furga G. ***Nature*** 2006 440(7084):631-6.
6. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Bürckstümmer T, Baumann C, Blüml S, Dixit E, Dürnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G. ***Nat Immunol*** 2009 Mar;10(3):266-72.
7. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, Burkard TR, Burckstummer T, Stefanovic A, Krieger S, Bennett KL, Rulicke T, Weber F, Colinge J, Muller M, Superti-Furga G. ***Nat Immunol*** 2011;12(7):624-630.
8. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiter S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G. ***Cell*** 2011, Oct 14;147(2):306-19.
9. Viral immune modulators perturb the human molecular network by common and unique strategies. Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, Habjan M, Binder M, Stefanovic A, Eberle CA, Goncalves A, Bürckstümmer T, Müller AC, Fauster A, Holze C, Lindsten K, Goodbourn S, Kochs G, Weber F, Bartenschlager R, Bowie AG, Bennett KL, Colinge J, Superti-Furga G. ***Nature***. 2012 Jul 26;487(7408):486-90.
10. Systems-pharmacology dissection of a drug synergy in imatinib resistant CML. Winter GE, Rix E, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G. ***Nat Chem Biol*** 2012, Nov;8(11):905-12.